ALFUZOSIN TABLET (EXTENDED-RELEASE)

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

ALFUZOSIN HYDROCHLORIDE

Dostupné s:

PRO DOC LIMITEE

ATC kód:

G04CA01

INN (Mezinárodní Name):

ALFUZOSIN

Dávkování:

10MG

Léková forma:

TABLET (EXTENDED-RELEASE)

Složení:

ALFUZOSIN HYDROCHLORIDE 10MG

Podání:

ORAL

Jednotky v balení:

100

Druh předpisu:

Prescription

Terapeutické oblasti:

Selective Alfa-1-Adrenergic Blocking Agents

Přehled produktů:

Active ingredient group (AIG) number: 0146806001; AHFS:

Stav Autorizace:

CANCELLED POST MARKET

Datum autorizace:

2018-11-30

Charakteristika produktu

_Alfuzosin _
_Page 1 of 38_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
ALFUZOSIN
Alfuzosin Hydrochloride
Prolonged-Release Tablets
10 mg
Pharmaceutical standard: Professed
SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
ADJUNCTIVE THERAPY IN ACUTE URINARY RETENTION (AUR)
ATC Code: G04CA01
PRO DOC LTÉE
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Date of Revision: August 11, 2017
Submission Control No.: 208229
_Alfuzosin _
_Page 2 of 38_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
3
WARNINGS AND
PRECAUTIONS........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTIONS
........................................................................................................
11
DOSAGE AND ADMINISTRATION
....................................................................................
13
OVERDOSAGE
......................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 14
STORAGE AND
STABILITY................................................................................................
19
SPECIAL HANDLING INSTRUCTIONS
.............................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 19
PART II: SCIENTIFIC INFORMATION
...........................................